DaVita Stock Declines 1.2% in 3 Months: Here's How to Play [Yahoo! Finance]
Unicycive Therapeutics, Inc. (UNCY)
Company Research
Source: Yahoo! Finance
have lost 1.2% in the past three months in contrast to the industry and the sector's 2.6% and 1.1% gains, respectively. The stock has, however, outperformed the S&P 500's 3.6% decline. A major development at DVA in recent months was the announcement of its promising fourth-quarter 2024 results in February. The company reported robust improvement in the top and bottom lines in the fourth quarter of 2024. Strength in segmental revenues during the quarter was also recorded. On the earnings call, management confirmed that within U.S. dialysis, DVA continued to benefit from innovation in its revenue cycle operations. Enhanced collection performance and contracting propelled higher revenue per treatment growth during the quarter. Howev
Read more
Impact Snapshot
Event Time:
UNCY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
UNCY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
UNCY alerts
High impacting Unicycive Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
UNCY
News
- Unicycive Therapeutics Announces Full Year 2024 Financial Results and Provides Business UpdateGlobeNewswire
- Unicycive to Highlight Patient Reported Outcomes Data at Upcoming Medical Meetings Showing Oxylanthanum Carbonate Reduced Pill Burden and Improved Adherence in Treatment of Hyperphosphatemia [Yahoo! Finance]Yahoo! Finance
- Unicycive to Highlight Patient Reported Outcomes Data at Upcoming Medical Meetings Showing Oxylanthanum Carbonate Reduced Pill Burden and Improved Adherence in Treatment of HyperphosphatemiaGlobeNewswire
- Unicycive Therapeutics Announces the Publication of Preclinical Data on Synergies Between Oxylanthanum Carbonate and Tenapanor in American Society of Nephrology Journal Kidney360GlobeNewswire
- Unicycive Therapeutics, Inc. (NASDAQ: UNCY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.MarketBeat
UNCY
Sec Filings
- 3/31/25 - Form 10-K
- 2/19/25 - Form 4
- 2/14/25 - Form SCHEDULE
- UNCY's page on the SEC website